Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Xeris Biopharma Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Xeris Biopharma Holdings, Inc.’s stock price such as:

• Xeris Biopharma Holdings, Inc.’s current stock price and volume
• Why Xeris Biopharma Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for XERS from analysts
• XERS’s stock price momentum as measured by its relative strength

About Xeris Biopharma Holdings, Inc. (XERS)

Before we jump into Xeris Biopharma Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Want to learn more about Xeris Biopharma Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Xeris Biopharma Holdings, Inc..

Xeris Biopharma Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Xeris Biopharma Holdings, Inc.’s stock price was $8.080.

Xeris Biopharma Holdings, Inc. is down 4.04% from its previous closing price of $8.420.

During the last market session, Xeris Biopharma Holdings, Inc.’s stock traded between $7.990 and $8.400. Currently, there are approximately 170.52 million shares outstanding for Xeris Biopharma Holdings, Inc..

Xeris Biopharma Holdings, Inc.’s price-earnings (P/E) ratio is currently at 126.3, which is high compared to the Pharmaceuticals industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Xeris Biopharma Holdings, Inc. Stock Price History

Xeris Biopharma Holdings, Inc.’s (XERS) price is currently up 2.02% so far this month.

During the month of July, Xeris Biopharma Holdings, Inc.’s stock price has reached a high of $9.020 and a low of $7.850.

Over the last year, Xeris Biopharma Holdings, Inc. has hit prices as high as $10.080 and as low as $4.870. Year to date, Xeris Biopharma Holdings, Inc.’s stock is up 2.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Xeris Biopharma Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Xeris Biopharma Holdings, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Xeris Biopharma Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Xeris Biopharma Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Xeris Biopharma Holdings, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Xeris Biopharma Holdings, Inc. (XERS) by visiting AAII Stock Evaluator.

Relative Price Strength of Xeris Biopharma Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Xeris Biopharma Holdings, Inc. has a weighted four-quarter relative price strength of 15.99%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Xeris Biopharma Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Xeris Biopharma Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, Xeris Biopharma Holdings, Inc.’s stock price is $8.080, which is down 4.04% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Xeris Biopharma Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.